NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT IS FILED AND ONLY THROUGH AN INTERMEDIARY’S PLATFORM. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. "RESERVING" SECURITIES IS SIMPLY AN INDICATION OF INTEREST.

Invest in Vita Imaging

Medical Device Company Developing Breakthrough Skin Cancer Detection in Real Time

$ 0 B
Projected size of the Global Cancer Diagnostics Market
$ 0 M
Invested in
commercialization
of the AURA
0 years
Over 20 years R&D by BCCA and UBC
2 seconds
Our award-winning AURA™ device helps detect skin cancer in two seconds
1 IN 5

Americans will develop skin cancer before age 70

>2 PEOPLE

Die of skin cancer in the U.S. every hour

$8.1 BILLION

Annual cost for treating all skin cancers: about $4.8B for nonmelanoma and $3.3B for melanoma

5.4 MILLON

People are treated for skin cancer yearly.

9,500 people are diagnosed with skin cancer every day

However, most healthcare providers still rely on visual inspection of suspicious lesions, sometimes with dermatoscopes for magnification, to identify potential skin cancer concerns, leading many physicians to excise or biopsy lesions as a precautionary procedure. These biopsies cost an estimated $1.6B annually and 95% of suspicious lesions are later found to be benign. 

“WHEN DETECTED EARLY, THE FIVE YEAR SURVIVAL RATE FOR MELANOMA IS 94%”

Our licensed, patent-protected diagnostics platform capable of generating accurate, objective results in real-time
Vita Imaging believes there is an urgent need for physician support tools such as AURA™, which can improve diagnostic accuracy and significantly reduce the need for invasive and costly biopsies. AURA™ works by utilizing proven Raman spectroscopy technology to differentiate between benign and malignant lesions, and provide nearly instantaneous results. It’s also non-invasive and requires little training to use, meaning it can be quickly and easily deployed in any dermatological clinic.

Meet AURA™

Skin Cancer: The Solution

Presenting the Vita Imaging AURA
Non-invasive Raman Spectroscopy device identifies benign vs. malignant lesions
Fastest results (under 1.5 seconds) and higher accuracy for ruling “in” disease
90% sensitivity; 82% specificity
95% sensitivity; 68% specificity
Settings are adjustable based on Physician need or preference
Sensitivity of diagnosing melanoma is 40.2% for primary care physicians
Sensitivity of diagnosing melanoma 49.0% - 67.9% for dermatologists
User friendly with little training required by healthcare professionals

AURA: Three Easy Steps

Step 1

Power up the AURA Imaging Device

Step 2

Scan the Affected Area Using the Light Probe Instant Result ( < 1.5sec)

Step 3

Review Display for Diagnosis & Recommended Next Steps

AURA Development –Past to Present

Over 20 years R&D by British Columbia Cancer Agency (BCCA), University of British Columbia, Verisante.
Industry & Research investment of $ 2 0 million to commercialize AURA

Sir CV raman’s original system (1928)

Rapid raman system built at the bc cancer agency (2002)

Beta test version

Retail product (2012)

VITA IMAGING’S AURA (2023)

AURA Development –Past to Present

Over 20 years R&D by British Columbia Cancer Agency (BCCA), University of British Columbia, Verisante.
Industry & Research investment of $ 2 0 million to commercialize AURA
Sir CV raman’s original system (1928)
Rapid raman system built at the bc cancer agency (2002)
Beta test version
Retail product (2012)
VITA IMAGING’S AURA (2023)

Proven Technology

Secured exclusive license

from the British Columbia Cancer Agency and the University of British Columbia

20 years

of extensive research and development

Backed by

a comprehensive patent portfolio

To date, the AURA™ has been tested in comprehensive clinical studies – including the largest known study using Raman technology for skin cancer detection – and has successfully passed all product performance and safety tests. Through this process, we believe that AURA™ has strong potential to exceed FDA benchmarks, ideally paving the way for full clearance and commercialization as a Class 3 medical device. 
Invest now on StartEngine

Featured On

Frame 1000001791
Frame 1000001792
Frame 1000001793
Frame 1000001794
Frame 1000001795
Frame 1000001796
Frame 1000001797

What’s Next

REGULATORY & GO-TO-MARKET TIMELINE: The Road Ahead
2022

FDA Submission September BriteLab (OEM)

2023

US Clinical Study August-December Manufacturing Audit

2024

Multi-site Clinical & MRMC Studies

Q1 Q2/25*
Q1 Q2/25*

FDA Approval Class 3

2025

US Launch AURA

2026

EU, UK AURA

2027

Asia (select markets) AURA

*AURA is a Class 3 PMA Device. FDA approval is, on average, 3 years for this device class.

Why Invest

Helping Save Lives One Diagnosis at a Time
AURA developed by leading scientists and physicians at the well-respected BCCA
Over 20 years R&D by BCCA and UBC - $20 million investment in commercialization of the AURA
Robust patent portfolio asset and strong IP position is a competitive advantage
Future revenue opportunity from Platform Technology: CORE & other cancer detection products
Vita retains ownership of data collected by Providers and builds comprehensive database using AI/Machine Learning. Data is a valuable asset commanding high valuation upon exit.
Billing code application in planning ( for insurance re-imbursement)

Our Experienced Team is Unmatched 

Thinh Tran • CEO & Chairman

Mr. Tran was the Founder, CEO, & Chairman of V-Silicon, a leader in the Smart TV market delivering best in class picture and audio quality. He was previously the Founder, Chairman, & CEO of Sigma Designs since its inception in 1982 which he built from a humble start-up a publicly traded NASDAQ company, at one point was valued at two billion dollars in 2007, before leaving in 2018…

Maria Victoria ReadeCOO

Ms. Reade has 25+ years of executive leadership and consulting experience including: Executive Director, MCO Operations & MSO at Scripps Clinic & Green Hospital La Jolla; VP, Medical Management at HMO Pacificare, Healthcare/IT Consultant at Deloitte, TMI, Pharma & Medtech…

Dzung Kim Tran WrightCFO

Ms. Wright is the Chief Financial Officer of Vita Imaging, Inc. She has over 30 years of experience in the financial industry, holding senior financial positions at multiple publicly traded and startup companies over a wide range of industries such as medical, telecommunications, device technology, digital arts, mobile devices, and internet technology…

We Invite You to Invest and Secure Equity in Vita Imaging!

Join us as we aim to deploy our technology where it’s needed most and defy cancer on a worldwide scale.

Invest now on StartEngine
Invest now on StartEngine

©2024 All Rights Reserved

Learn more about investing in SmartDrone!

Submit your details to explore our StartEngine page and access our investor deck, showcasing how our LiDAR-powered drones are transforming land surveying, construction, and engineering with speed, accuracy, and efficiency.

Have you invested in startups before?